Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Justin Sullivan/Getty Images

Gilead will charge U.S. hospitals $3,120 for the shortest treatment course of its coronavirus drug remdesivir for typical patients with private insurance, according to an open letter from CEO Daniel O’Day.

Why it matters: It is the first antiviral drug shown to effectively treat coronavirus in a major clinical trial, and Gilead's pricing decision may set the bar for how future treatments will be priced.

  • Its benefits remain rather limited, as patients on the drug leave the hospital in 11 days versus 15 days.
  • It also did not lead to a statistically significant drop in deaths.

By the numbers: Gilead will charge two prices for the drug in the U.S. — one for patients with private insurance and a second, lower price for government health agencies like the Department of Veterans Affairs. The lower price will not be extended to government programs that do not directly purchase medicines, like Medicare

  • The government price will be $390 per dose, or $2,340 per patient for the shortest treatment course of five days and $4,290 for a longer treatment course of 10 days.
  • Nongovernment buyers will pay around $520 per dose — about a third more than the government price — for patients with private insurance, or approximately $3,120 for the shorter treatment and $5,720 for the longer treatment.
  • O’Day told the Wall Street Journal that 90% to 95% of patients currently receive the shorter, five-day treatment course.

The big picture: Gilead will only charge two separate prices in the U.S. It will charge the government price in other developed nations with public insurance programs.

  • "Part of the intent behind our decision was to remove the need for country by country negotiations on price. We discounted the price to a level that is affordable for developed countries with the lowest purchasing power," O'Day said.

Worth noting: Estimates from experts at the Institute for Clinical and Economic Review said last week that the cost of a course of remdesivir should not exceed $2,800.

Go deeper: Wall Street forecasts blockbuster sales for Gilead's coronavirus drug remdesivir

Editor's note: This story has been corrected to reflect that the lower price will be extended to government agencies, but not programs like Medicare that don’t directly purchase medicines.

Go deeper

Oct 6, 2020 - Health

Doctor on Demand CEO: COVID has changed the telehealth industry

Doctor on Demand CEO Hill Ferguson. Photo: Axios.

The coronavirus pandemic has created unprecedented opportunities for growth
in the telehealth industry, including treating mental health and chronic conditions like diabetes, Hill Ferguson, the CEO of Doctor on Demand, told Axios at a virtual event on Tuesday.

What's changed: "Everything from reimbursements, paying providers for telemedicine in places where that wasn't possible, lowering interstate licensing laws that was prohibiting physicians from treating patients over interstate boundaries has been relaxed, patients are now aware of telemedicine at much higher rates than they were before," he said.

Aug 25, 2020 - Health

Hahn says criticism of his remarks on plasma treatment for coronavirus justified

FDA commissioner Stephen Hahnduring a press conference at the White House on Sunday. Photo: Pete Marovich/Getty Images

FDA commissioner Stephen Hahn said in a Twitter thread Monday night criticisms of his comments about granting an emergency use authorization (EUA) of convalescent plasma as a treatment for the coronavirus were "entirely justified."

The big picture: Hahn also addressed in his post the politicization of the FDA, in an apparent reference to President Trump and his trade adviser, Peter Navarro, accusing senior health officials of being part of the "Deep State" amid a decision to put the plasma treatment on hold.

White House physician says Trump reports no COVID-19 symptoms

Photo: Win McNamee/Getty Images

President Trump was not experiencing coronavirus symptoms Tuesday and is doing "extremely well," according to a memo released by White House physician Sean Conley.

The state of play: Trump was discharged from Walter Reed Medical Center on Monday evening and returned to the White House to continue his treatment. Conley said in a briefing on Monday that while the president's condition is improving, he "may not be entirely out of the woods yet" and the next few days will be critical to the course of his recovery.